World AIDS Vaccine Day 2026: What HIV Vaccine Research Is Testing Now

Key Takeaways

• European HIV vaccine R&D funding dropped from $16.5 M to $9.9 M (2009‑2020).
• bnAb study found single‑amino‑acid changes can confer resistance.
• IAVI G004 uses Moderna mRNA platform in 96‑person South African Phase I trial.
• Scripps received $1.1 M to apply AI for faster antibody‑vaccine modeling.

Pulse Analysis

The HIV prevention arena is being reshaped by new biomedical tools. FDA approval of Gilead’s lenacapavir injectable PrEP in mid‑2025 adds a twice‑yearly option, but uneven testing access and rising infection rates keep Europe off‑track on key targets. Declining public funding—down from roughly $16.5 million in 2009 to $9.9 million in 2020—has eroded the continent’s research infrastructure, raising concerns that Europe could lose critical expertise in immunogen design and structural biology.

Scientific breakthroughs are emerging despite fiscal headwinds. A recent Nature Microbiology analysis demonstrated that HIV can sidestep single broadly neutralizing antibodies (bnAbs) with just one amino‑acid substitution, underscoring the need for carefully engineered antibody cocktails. In parallel, African-led trials such as IAVI’s G004 and the BRILLIANT 011 study are leveraging Moderna’s mRNA platform to present novel immunogens to 96 volunteers across South Africa, aiming to steer B‑cells toward bnAb production against region‑specific viral strains. These efforts illustrate a strategic pivot toward combination immunogen designs that anticipate viral escape.

Artificial intelligence is accelerating the design loop. Scripps Research secured a $1.1 million grant to deploy high‑performance computing for rapid antibody‑vaccine modeling, shortening the time from data collection to candidate selection. By simulating molecular interactions at scale, AI can identify promising epitopes and predict resistance pathways before costly clinical phases. The convergence of AI, mRNA technology, and renewed African trial activity offers a pragmatic path forward, but sustained, coordinated funding—especially in Europe—remains essential to keep the global HIV vaccine pipeline robust and inclusive.